Repurposing of the ALK Inhibitor Crizotinib for Acute Leukemia and Multiple Myeloma Cells

Crizotinib was a first generation of ALK tyrosine kinase inhibitor approved for the treatment of <i>ALK</i>-positive non-small-cell lung carcinoma (NSCLC) patients. COMPARE and cluster analyses of transcriptomic data of the NCI cell line panel indicated that genes with different cellular functions r...

Disgrifiad llawn

Manylion Llyfryddiaeth

Prif Awduron:	Joelle C. Boulos, Mohamed E. M. Saeed, Manik Chatterjee, Yagmur Bülbül, Francesco Crudo, Doris Marko, Markus Munder, Sabine M. Klauck, Thomas Efferth
Fformat:	Artigo
Iaith:	Inglês
Cyhoeddwyd:	MDPI AG 2021-11-01
Cyfres:	Pharmaceuticals
Pynciau:	acute myeloid leukemia drug repurposing multiple myeloma network pharmacology transcriptomics tyrosine kinase inhibitors
Mynediad Ar-lein:	https://www.mdpi.com/1424-8247/14/11/1126
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!